<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Granulocytic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> (GS) is an extramedullary <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> composed of immature myeloid cells </plain></SENT>
<SENT sid="1" pm="."><plain>The objectives of this study were to describe the frequency, presenting characteristics, and survival in patients with nonleukemic GS by conducting a review of <z:hpo ids='HP_0000001'>all</z:hpo> untreated patients presenting to the MD Anderson <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center between January 1990 and June 2002 </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 21 patients with nonleukemic GS, 1520 patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and 402 patients with high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) were identified </plain></SENT>
<SENT sid="3" pm="."><plain>GS occurred in 1.4% of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and 1.1% of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or high-risk MDSs </plain></SENT>
<SENT sid="4" pm="."><plain>The median patient age was 57 years (range, 7-81) </plain></SENT>
<SENT sid="5" pm="."><plain>Among 20 patients with available cytogenetics in tissue and/or bone marrow, six had chromosome 8 abnormalities </plain></SENT>
<SENT sid="6" pm="."><plain>The median follow-up of surviving patients is 12 months (range, 7-75) </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 20 patients were treated </plain></SENT>
<SENT sid="8" pm="."><plain>Patients were treated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-type chemotherapy (n=16), chemotherapy and radiotherapy (n=3), or radiotherapy alone (n=1) </plain></SENT>
<SENT sid="9" pm="."><plain>A total of 13 patients (65%) achieved complete remission and one patient (5%) achieved partial remission </plain></SENT>
<SENT sid="10" pm="."><plain>The median overall survival was 20 months (range, 1-75), median overall failure-free survival was 12 months (range, 1-75) </plain></SENT>
<SENT sid="11" pm="."><plain>The median survival of patients with chromosome 8 abnormalities was 12 months compared with 40 months of those without (P=0.17) </plain></SENT>
<SENT sid="12" pm="."><plain>Novel therapies for patients with GS are required </plain></SENT>
</text></document>